Immunomodulating therapy in liver transplantation: Principles and practice

Jody C. Olson, Russell H. Wiesner

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Liver transplantation has enjoyed dramatic success as a treatment option for patients suffering from chronic end-stage liver diseases. It also serves as a definitive treatment for certain genetic conditions such as familial amyloidosis and primary oxalosis, and as a potential curative therapy in selected cases of primary liver cancer. Currently, over 50,000 patients are alive with functioning liver transplants. Liver transplantation owes its success to advances in surgical technique, improvements in anesthesia and critical care, and advances in treatment of post-transplant complications including improved therapies for cytomegalovirus infections. But perhaps the most important advances in liver transplantation arise in the context of improvements in our understanding of the molecular biology of transplant immunology and the development of new agents that allow for manipulation of immunological signaling pathways. These improvements in immunosuppressive therapy have dramatically increased both graft and patient survival.

Original languageEnglish (US)
Pages (from-to)793-805
Number of pages13
Issue number8
StatePublished - Aug 1 2012


  • azathioprine
  • cyclosporine
  • immunosuppression
  • liver
  • mycophenolate mofetil
  • sirolimus
  • tacrolimus
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Immunomodulating therapy in liver transplantation: Principles and practice'. Together they form a unique fingerprint.

Cite this